Lisata Therapeutics, Inc. has filed an amendment to its previous report concerning the acquisition of Marea Therapeutics, Inc. This update, filed on November 19, 2026, includes significant financial information that may provide investors with a clearer picture of the merger's implications.
The amendment, labeled as Amendment No. 2, revises the original report filed on September 17, 2026, which announced the completion of the acquisition. The latest filing aims to enhance the financial disclosures by including unaudited pro forma combined statements of operations for both companies.
Background
Lisata Therapeutics, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol LSTA. It is a smaller reporting company based in Basking Ridge, New Jersey, and has undergone several name changes in its history, previously known as Caladrius Biosciences, Inc. and NeoStem, Inc.
What the Filing Says
The filing states, "This Amendment No. 2 to the Original Report is being filed solely to amend Item 9.01 of the Original Report to include the unaudited pro forma combined statement of operations of the Company for the nine months ended September 30, 2026 and the year ended December 31, 2025." This amendment is crucial as it provides updated financial information that reflects the merger's operational impact.
Impact
This update may significantly affect investors and stakeholders in Lisata Therapeutics as they assess the financial health and future prospects of the combined entity. The pharmaceutical industry as a whole may also experience changes as companies look to consolidate and strengthen their market positions through similar acquisitions.
What's Next
The filing does not say what happens next, leaving investors to await further announcements regarding the integration of Marea Therapeutics into Lisata's operations.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




